Jefferies Provides Color on Seattle Genetics

According to a recent report from Jefferies, A new protocol amendment is being implemented for the Adcentris expanded access program that will bode well for Seattle Genetics SGEN. The new protocol will allow second-line, pre-transplant patients to participate in the Adcentris expanded access program. In the report, Jefferies said, "We view this as a positive signal of the potential for Adcentris to receive a broad FDA label that covers second-line Hodgkin lymphoma in addition to the third-line and salvage population treated in the pivotal trial." Seattle Genetics closed Friday at $18.94.